02
Feb

Generics giant Mylan is shouldering its way into the blockbuster market for COPD treatments, signing a $265 million deal with the respiratory experts at Theravance Biopharma to get its hands on a late-stage contender.

…read more

Source: Mylan buys into Theravance’s COPD contender in $265M deal

    

0 No comments